Clinical Trials
142 trialsA Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Taiho Oncology, Inc.
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Taiho Oncology, Inc.
BHARAT-1
Aurigene Discovery Technologies Limited
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
GluBio Therapeutics Inc.
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Beijing InnoCare Pharma Tech Co., Ltd.
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
TScan Therapeutics, Inc.
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Bristol-Myers Squibb
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
Seagen Inc.
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd.
LIMBER
Incyte Corporation
LAUREL
Inmune Bio, Inc.
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
Novartis
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
Remedy Plan, Inc.
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
NextCure, Inc.
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Cullinan Therapeutics Inc.
A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS
Janssen Research & Development, LLC
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
DHODH
Janssen Research & Development, LLC
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Celgene
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Amgen
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics Inc.
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Celgene
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Servier
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Janssen Research & Development, LLC
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc.
Study of REM-422 in Patients With AML or Higher Risk MDS
Remix Therapeutics
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
Aptose Biosciences Inc.
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NovaOnco Therapeutics Co., Ltd.
8479217
BerGenBio ASA
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta, Inc.
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
Precigen, Inc
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Ascentage Pharma Group Inc.